MC225A7 - Substitutes 2- (2,6-Dioxopiperidin-3-yl) -phthalimides and-1-oxo-iso-indolines and methods for reducing tnf-alpha levels - Google Patents
Substitutes 2- (2,6-Dioxopiperidin-3-yl) -phthalimides and-1-oxo-iso-indolines and methods for reducing tnf-alpha levelsInfo
- Publication number
- MC225A7 MC225A7 MC225K MC225K MC225A7 MC 225 A7 MC225 A7 MC 225A7 MC 225 K MC225 K MC 225K MC 225 K MC225 K MC 225K MC 225 A7 MC225 A7 MC 225A7
- Authority
- MC
- Monaco
- Prior art keywords
- carbon atoms
- hydrogen
- alkyl
- dioxopiperidin
- indolines
- Prior art date
Links
- FPNJYPLJTAYAMP-UHFFFAOYSA-N 7a-(2,6-dioxopiperidin-3-yl)-3ah-isoindole-1,3-dione Chemical class C1=CC=CC2C(=O)NC(=O)C21C1CCC(=O)NC1=O FPNJYPLJTAYAMP-UHFFFAOYSA-N 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- -1 m -phenylene Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005605 benzo group Chemical group 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical compound O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
1. A 2,6-dioxopiperidine selected from the group consisting of
( a ) a compound of the formula:
in which:
one of X and Y is C=O and the other of X and Y
( i ) each of R 1 , R 2 , R 3 , and R 4 , independently of yl of 1 to 4 carbon atoms, or alkoxy of 1 to 4 carbon atoms or ( ii ) one of R 1 , R 2 , R 3 , and R 4 is -NHR 5 and the remaining of R 1 , R 2 , R 3 , and R 4 are hydrogen;
R 5 is hydrogen, alkyl of 1 to 8 carbon atoms, or CO-R 7 -CH(R 10 )NR 8 R 9 ;
R 6 is hydrogen, alkyl of 1 to 8 carbon atoms, benzo, chloro, or fluoro;
R 7 is m -phenylene or p -phenylene or -(C n H 2 n )- in which n has a value of 0 to 4; each of R 8 and R 9 taken independently of the other is hydrogen or alkyl of 1 to 8 carbon atoms, or R 8 and R 9 taken together are tetramethylene, pentamethylene, hexamethylene, or -CH 2 CH 2 XCH 2 CH 2 - in which X is -O-, -S- or -NH-;
R 10 is hydrogen, alkyl of 1 to 8 carbon atoms, or phenyl; and
( b ) the acid addition salts of said compounds which contain a nitrogen atom capable of being protonated.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4827897P | 1997-05-30 | 1997-05-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
MC225A7 true MC225A7 (en) | 2006-03-07 |
Family
ID=21953674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MC225K MC225A7 (en) | 1997-05-30 | 2005-08-11 | Substitutes 2- (2,6-Dioxopiperidin-3-yl) -phthalimides and-1-oxo-iso-indolines and methods for reducing tnf-alpha levels |
Country Status (25)
Country | Link |
---|---|
US (3) | US6395754B1 (en) |
EP (3) | EP1486496B1 (en) |
JP (2) | JP4307567B2 (en) |
KR (1) | KR100526212B1 (en) |
CN (3) | CN1911927A (en) |
AT (2) | ATE401319T1 (en) |
AU (1) | AU741982B2 (en) |
CA (2) | CA2291218C (en) |
CY (1) | CY1108348T1 (en) |
CZ (1) | CZ299812B6 (en) |
DE (2) | DE69825994T2 (en) |
DK (2) | DK0984955T3 (en) |
ES (3) | ES2403102T3 (en) |
FI (1) | FI19992490A (en) |
HK (1) | HK1072248A1 (en) |
HU (2) | HU228769B1 (en) |
MC (1) | MC225A7 (en) |
NO (6) | NO322080B1 (en) |
NZ (1) | NZ501429A (en) |
PL (1) | PL193276B1 (en) |
PT (2) | PT1486496E (en) |
RU (1) | RU2209207C2 (en) |
SK (1) | SK163099A3 (en) |
TR (4) | TR200000107T2 (en) |
WO (1) | WO1998054170A1 (en) |
Families Citing this family (155)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US6429221B1 (en) | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US6518281B2 (en) * | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
SK7382000A3 (en) * | 1997-11-18 | 2000-12-11 | Celgene Corp | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines, pharmaceutical composition containing the same and their use |
CN100390163C (en) * | 1998-03-16 | 2008-05-28 | 赛尔金有限公司 | 2-(2,6-dioxopiperidin-3-yl)-isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
ES2250121T3 (en) | 1999-03-18 | 2006-04-16 | Celgene Corporation | 1-OXO- AND 1,3-DIOXOISOINDOLINAS AND ITS EMPLOYMENT IN PHARMACEUTICAL COMPOSITIONS FOR THE REDUCTION OF LEVELS OF INFLAMMATORY CITOCINES. |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
US6458810B1 (en) | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
ATE374609T1 (en) * | 2000-11-30 | 2007-10-15 | Childrens Medical Center | SYNTHESIS OF 4-AMINOTHALIDOMIDE ENANTIOMERS |
US20030045552A1 (en) * | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
US7091353B2 (en) | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
JP2005536189A (en) * | 2002-04-12 | 2005-12-02 | セルジーン・コーポレーション | Method for identifying modulators of angiogenesis, compounds found thereby and therapeutic methods using the compounds |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
CN1697655B (en) | 2002-05-17 | 2013-09-18 | 细胞基因公司 | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
NZ536908A (en) * | 2002-05-17 | 2008-09-26 | Celgene Corp | Treating or preventing cancer comprising administering an effective amount of cytokine inhibitory drug plus a second active ingredient |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
EP1551385A4 (en) * | 2002-10-15 | 2008-10-22 | Celgene Corp | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
US8404716B2 (en) | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
EP1900369A1 (en) | 2002-10-15 | 2008-03-19 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes |
US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US20040087558A1 (en) * | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
AU2003286663B2 (en) * | 2002-10-24 | 2009-08-13 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
NZ540186A (en) * | 2002-10-31 | 2008-03-28 | Celgene Corp | Composition for the treatment of macular degeneration |
US20040091455A1 (en) * | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
MXPA05004780A (en) | 2002-11-06 | 2005-10-05 | Celgene Corp | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases. |
US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
US8034831B2 (en) * | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
BR0316256A (en) * | 2002-11-18 | 2005-10-04 | Celgene Corp | Methods of inhibiting tnf-alpha production and pde4 activity, treating or preventing a disease or disorder, controlling camp levels in a cell and producing a compound, pharmaceutical composition and compound |
JP2006510617A (en) * | 2002-11-18 | 2006-03-30 | セルジーン・コーポレーション | Method of using (+)-3- (3,4-dimethoxy-phenyl) -3- (1-oxo-1,3-dihydro-isoindol-2-yl) -propionamide and compositions containing it |
US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
UA83504C2 (en) * | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US20080027113A1 (en) * | 2003-09-23 | 2008-01-31 | Zeldis Jerome B | Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration |
US7612096B2 (en) * | 2003-10-23 | 2009-11-03 | Celgene Corporation | Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline |
US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
EA200600921A1 (en) * | 2003-11-06 | 2006-10-27 | Селджин Корпорейшн | METHODS AND COMPOSITIONS WITH THE USE OF TALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CANCER AND OTHER DISEASES |
EP2065383A1 (en) | 2003-11-19 | 2009-06-03 | Signal Pharmaceuticals, Inc. | Indazole compounds and methods of use thereof as protein kinase inhibitors |
US20050143344A1 (en) * | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
NZ550026A (en) * | 2004-03-22 | 2009-10-30 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders |
US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
BRPI0418742A (en) * | 2004-04-14 | 2007-09-11 | Celgene Corp | methods of treating, preventing or controlling a myelodysplastic syndrome, reducing or preventing an adverse effect associated with the administration of a second active ingredient in a patient suffering from a myelodysplastic syndrome, pharmaceutical composition, single unit dosage form, and kit |
JP2007532642A (en) * | 2004-04-14 | 2007-11-15 | セルジーン・コーポレーション | Use of selective cytokine inhibitors for the treatment and management of myelodysplastic syndromes and compositions containing the same |
CA2563810A1 (en) * | 2004-04-23 | 2005-11-10 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
WO2005112928A1 (en) * | 2004-05-05 | 2005-12-01 | Celgene Corporation | Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases |
ZA200702382B (en) * | 2004-09-03 | 2008-08-27 | Celgene Corp | Processes for the preparation of substituted 2-(2,6-dioxoplperidin-3-yl)-1-oxoisoindolines |
BRPI0518062A (en) * | 2004-10-28 | 2008-10-28 | Celgene Corp | use of a pde4 modulator, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, and, pharmaceutical composition |
US20060122228A1 (en) * | 2004-11-23 | 2006-06-08 | Zeldis Jerome B | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
BRPI0607239A2 (en) * | 2005-01-25 | 2009-08-25 | Celgene Corp | uses of a therapeutically or prophylactically effective amount of (3r) -4-amino-2-4-amino-2- (3-methyl-2,6-dioxopiperidin-3-yl) -isoindol-1,3-dione - (3-methyl-2,6-dioxopiperidin-3-yl) isoindol-1,3-dione, and (3s) -4-amino-2- (3-methyl-2,6-dioxopiperidin-3-one) il) -isoindol-1,3-dione, or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical composition, and single unit dosage form |
CN100383139C (en) * | 2005-04-07 | 2008-04-23 | 天津和美生物技术有限公司 | Piperidine-2,6-dione derivatives capable of inhibiting cell from releasing tumor necrosis factor |
US20060270707A1 (en) * | 2005-05-24 | 2006-11-30 | Zeldis Jerome B | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus |
CA2613548A1 (en) * | 2005-06-30 | 2007-01-11 | Anthrogenesis Corporation | Repair of tympanic membrane using placenta derived collagen biofabric |
CA2612612C (en) | 2005-06-30 | 2014-03-11 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
US20070021762A1 (en) * | 2005-07-13 | 2007-01-25 | Qing Liu | Ocular plug formed from placenta derived collagen biofabric |
EP1919500A2 (en) * | 2005-07-13 | 2008-05-14 | Anthrogenesis Corporation | Treatment of leg ulcers using placenta derived collagen biofabric |
KR20080042158A (en) | 2005-08-31 | 2008-05-14 | 셀진 코포레이션 | Isoindole-imide compounds and compositions comprising and methods of using the same |
ES2359162T3 (en) | 2005-09-01 | 2011-05-19 | Celgene Corporation | IMMUNOLOGICAL USES OF IMMUNOMODULATING COMPOUNDS FOR VACCINES AND ANTI-INFECTIOUS DISEASE THERAPY. |
US20070066512A1 (en) * | 2005-09-12 | 2007-03-22 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
CN1939922B (en) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 5H-thiophene [3,4-C] pyrrole-4,6-diketone derivative for inhibiting cell release tumor necrosis factor |
MX343814B (en) | 2005-10-13 | 2016-11-24 | Anthrogenesis Corp | Immunomodulation using placental stem cells. |
KR20080097190A (en) * | 2005-12-29 | 2008-11-04 | 안트로제네시스 코포레이션 | Improved composition for collecting and preserving placental stem cells and methods of using the composition |
US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
US20080064876A1 (en) * | 2006-05-16 | 2008-03-13 | Muller George W | Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione |
CL2007002218A1 (en) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | USE OF 3- (4-AMINO-1-OXO-1,3-DIHIDRO-ISOINDOL-2-IL) -PIPERIDINE 2,6-DIONA FOR THE PREPARATION OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF LAYER CELL LYMPHOMA. |
WO2008021391A1 (en) * | 2006-08-15 | 2008-02-21 | Anthrogenesis Corporation | Umbilical cord biomaterial for medical use |
US8877780B2 (en) | 2006-08-30 | 2014-11-04 | Celgene Corporation | 5-substituted isoindoline compounds |
RU2448101C2 (en) * | 2006-08-30 | 2012-04-20 | Селджин Корпорейшн | 5-substituted isoindoline compounds |
MX2009001989A (en) * | 2006-08-30 | 2009-03-09 | Celgene Corp | 5-substituted isoindoline compounds. |
PL2420498T3 (en) | 2006-09-26 | 2017-10-31 | Celgene Corp | 5-substituted quinazolinone derivatives as anti-cancer agents |
WO2008042441A1 (en) * | 2006-10-03 | 2008-04-10 | Anthrogenesis Corporation | Use of umbilical cord biomaterial for ocular surgery |
US8071135B2 (en) | 2006-10-04 | 2011-12-06 | Anthrogenesis Corporation | Placental tissue compositions |
WO2008057162A2 (en) | 2006-10-06 | 2008-05-15 | Anthrogenesis Corporation | Native (telopeptide) placental collagen compositions |
CN101186611B (en) | 2006-11-15 | 2011-05-18 | 天津和美生物技术有限公司 | Pyrroline-2-one derivative capable of inhibiting cell to release tumor necrotic factor and its preparation and application |
NZ612888A (en) | 2007-02-12 | 2015-02-27 | Anthrogenesis Corp | Treatment of inflammatory diseases using placental stem cells |
JP2010518812A (en) * | 2007-02-12 | 2010-06-03 | アンスロジェネシス コーポレーション | Hepatocytes and chondrocytes derived from adherent placental stem cells, and enriched cell populations of CD34 +, CD45− placental stem cells |
US7893045B2 (en) | 2007-08-07 | 2011-02-22 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
CN101952272B (en) | 2007-09-26 | 2014-08-27 | 细胞基因公司 | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same |
KR20210022148A (en) | 2007-09-28 | 2021-03-02 | 안트로제네시스 코포레이션 | Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells |
EP2235213A2 (en) * | 2007-12-20 | 2010-10-06 | Celgene Corporation | Use of micro-rna as a biomarker of immunomodulatory drug activity |
WO2009105256A2 (en) * | 2008-02-20 | 2009-08-27 | Celgene Corporation | Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand |
SI2358697T1 (en) | 2008-10-29 | 2016-02-29 | Celgene Corporation | Isoindoline compounds for use in the treatment of cancer. |
WO2010093434A1 (en) | 2009-02-11 | 2010-08-19 | Celgene Corporation | Isotopologues of lenalidomide |
EP3489352A1 (en) | 2009-03-25 | 2019-05-29 | Celularity, Inc. | Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds |
ES2728776T3 (en) | 2009-05-19 | 2019-10-28 | Celgene Corp | 4-amino-2- (2,6-dioxopiperidin-3-yl) isoindolin-1,3-dione formulations |
EP2436387B1 (en) | 2009-05-25 | 2018-07-25 | Celgene Corporation | Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex |
CN101696205B (en) | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(substituted xylylenimine-2-yl)-2,6-dioxopiperidine polymorph and pharmaceutical composition |
CA2783616A1 (en) | 2009-12-22 | 2011-06-30 | Celgene Corporation | (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses |
CA2786266A1 (en) | 2010-01-05 | 2011-07-14 | Celgene Corporation | A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer |
EP4289838A3 (en) | 2010-02-11 | 2024-03-13 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
MX341050B (en) | 2010-04-07 | 2016-08-05 | Celgene Corp * | Methods for treating respiratory viral infection. |
US20140031325A1 (en) | 2010-12-06 | 2014-01-30 | Celgene Corporation | Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
AU2011352036A1 (en) | 2010-12-31 | 2013-07-18 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory RNA molecules |
US8853175B2 (en) | 2011-01-10 | 2014-10-07 | Celgene Corporation | Phenethylsulfone isoindoline derivatives and their use |
PE20140983A1 (en) | 2011-03-11 | 2014-08-25 | Celgene Corp | SOLID FORMS OF 3- (5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-IL) -PIPERIDIN-2,6-DIONA, AND ITS PHARMACEUTICAL COMPOSITIONS AND ITS USES |
US9090585B2 (en) | 2011-03-28 | 2015-07-28 | Deuterx, Llc | 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds |
MX2013012083A (en) | 2011-04-18 | 2014-04-16 | Celgene Corp | Biomarkers for the treatment of multiple myeloma. |
KR20140024914A (en) | 2011-04-29 | 2014-03-03 | 셀진 코포레이션 | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
WO2012166844A2 (en) | 2011-06-01 | 2012-12-06 | Anthrogenesis Corporation | Treatment of pain using placental stem cells |
US20140221427A1 (en) | 2011-06-22 | 2014-08-07 | Celgene Corporation | Isotopologues of pomalidomide |
MX356105B (en) | 2011-09-14 | 2018-05-14 | Celgene Corp | Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4 -methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-i soindol-4-yl}-amidecelgene corporation state of incorporation:delaware. |
HUE050327T2 (en) | 2011-12-27 | 2020-11-30 | Amgen Europe Gmbh | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione |
WO2013182660A1 (en) | 2012-06-06 | 2013-12-12 | Bionor Immuno As | Hiv vaccine |
ES2872967T3 (en) | 2012-06-29 | 2021-11-03 | Celgene Corp | Methods to determine drug efficacy using IKZF3 (AIOLOS) |
ES2755748T3 (en) | 2012-07-27 | 2020-04-23 | Celgene Corp | Procedures for preparing isoindolin-1,3-dione compounds |
AU2013299631B2 (en) | 2012-08-09 | 2017-09-28 | Celgene Corporation | Salts and solid forms of (S)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same |
US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
EA201590535A1 (en) | 2012-09-10 | 2015-07-30 | Селджин Корпорейшн | METHODS OF TREATMENT OF LOCALLY PROGRESSIVE RUNNING BREAST CANCER |
WO2014110558A1 (en) | 2013-01-14 | 2014-07-17 | Deuterx, Llc | 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
AU2014215458A1 (en) | 2013-02-05 | 2015-08-13 | Anthrogenesis Corporation | Natural killer cells from placenta |
EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
WO2014152833A1 (en) | 2013-03-14 | 2014-09-25 | Deuterx, Llc | 3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives |
AU2014254056B2 (en) | 2013-04-17 | 2019-06-06 | Signal Pharmaceuticals, Llc | Combination therapy comprising a TOR kinase inhibitor and an IMiD compound for treating cancer |
WO2015007337A1 (en) | 2013-07-19 | 2015-01-22 | Bionor Immuno As | Method for the vaccination against hiv |
EP3160486B1 (en) | 2014-06-27 | 2020-11-18 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases |
RS64038B1 (en) | 2014-08-22 | 2023-04-28 | Celgene Corp | Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies |
RU2695521C9 (en) | 2014-10-30 | 2019-08-19 | Канпу Биофармасьютикалс, Лтд. | Производное изоиндолина, промежуточный продукт, способ получения, фармацевтическая композиция и ее применение |
SI3313818T1 (en) | 2015-06-26 | 2024-03-29 | Celgene Corporation | Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers |
US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
ITUB20169994A1 (en) | 2016-01-14 | 2017-07-14 | Phf Sa | New crystalline forms of immunomodulatory drugs |
BR112019011025A2 (en) | 2016-12-03 | 2019-10-08 | Juno Therapeutics Inc | T cell modulation methods |
PT3618842T (en) | 2017-05-01 | 2024-01-12 | Juno Therapeutics Inc | Combination of a cell therapy and an immunomodulatory compound |
US11413310B2 (en) | 2017-06-02 | 2022-08-16 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
MX2019015155A (en) | 2017-06-29 | 2020-08-03 | Juno Therapeutics Inc | Mouse model for assessing toxicities associated with immunotherapies. |
US20200246393A1 (en) | 2017-09-28 | 2020-08-06 | Celularity, Inc. | Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody |
WO2019089858A2 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
MA49911A (en) | 2017-11-01 | 2020-06-24 | Juno Therapeutics Inc | ANTIBODIES AND CHEMERICAL ANTIGENIC RECEPTORS SPECIFIC TO THE B-LYMPHOCYTE MATURATION ANTIGEN |
CN111372585A (en) | 2017-11-16 | 2020-07-03 | C4医药公司 | Degradants and degreddeterminants for target protein degradation |
US12006356B2 (en) | 2017-12-15 | 2024-06-11 | Juno Therapeutics, Inc. | Anti-CCT5 binding molecules and chimeric antigen receptors comprising the same |
CA3092037A1 (en) | 2018-02-21 | 2019-08-29 | Celgene Corporation | Bcma-binding antibodies and uses thereof |
WO2019191112A1 (en) | 2018-03-26 | 2019-10-03 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
EP3781156A4 (en) | 2018-04-16 | 2022-05-18 | C4 Therapeutics, Inc. | Spirocyclic compounds |
EP3846800A4 (en) | 2018-09-04 | 2022-08-24 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
CA3117978A1 (en) | 2018-11-08 | 2020-05-14 | Juno Therapeutics, Inc. | Methods and combinations for treatment and t cell modulation |
EP3880669A1 (en) | 2018-11-13 | 2021-09-22 | Biotheryx, Inc. | Substituted isoindolinones |
BR112021009420A2 (en) | 2018-11-16 | 2021-11-23 | Juno Therapeutics Inc | Engineered t-cell dosing methods for the treatment of b-cell malignancies |
US20220088070A1 (en) | 2018-11-30 | 2022-03-24 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
JP7494181B2 (en) | 2018-12-19 | 2024-06-03 | セルジーン コーポレイション | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith - Patents.com |
CN113453679A (en) | 2018-12-20 | 2021-09-28 | C4医药公司 | Targeted protein degradation |
EP3917570A1 (en) | 2019-01-29 | 2021-12-08 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
EP3935050A4 (en) | 2019-03-06 | 2023-01-04 | C4 Therapeutics, Inc. | Heterocyclic compounds for medical treatment |
MX2023008296A (en) | 2021-01-13 | 2023-09-29 | Monte Rosa Therapeutics Inc | Isoindolinone compounds. |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023250400A1 (en) | 2022-06-22 | 2023-12-28 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3378763D1 (en) * | 1982-04-02 | 1989-02-02 | Takeda Chemical Industries Ltd | Condensed pyrrolinone derivatives, and their production |
CA1284647C (en) * | 1986-12-25 | 1991-06-04 | Kazuhiro Kubo | Isoindolin-1-one derivative and anti-arrhythmic agent |
US4808402A (en) * | 1987-05-29 | 1989-02-28 | Northwestern University | Method and compositions for modulating neovascularization |
DK24089D0 (en) * | 1989-01-20 | 1989-01-20 | Hans Bundgaard | NOVEL PRODRUG DERIVATIVES OF BIOLOGICALLY ACTIVE AGENTS CONTAINING HYDROXYL GROUPS OR NH-ACIDIC GROUPS |
GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
WO1992014455A1 (en) * | 1991-02-14 | 1992-09-03 | The Rockefeller University | METHOD FOR CONTROLLING ABNORMAL CONCENTRATION TNF α IN HUMAN TISSUES |
ES2098505T3 (en) * | 1991-04-17 | 1997-05-01 | Gruenenthal Chemie | NEW DERIVATIVES OF THALIDOMIDE, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. |
US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US6228879B1 (en) * | 1997-10-16 | 2001-05-08 | The Children's Medical Center | Methods and compositions for inhibition of angiogenesis |
US20010056114A1 (en) * | 2000-11-01 | 2001-12-27 | D'amato Robert | Methods for the inhibition of angiogenesis with 3-amino thalidomide |
US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
DE4422237A1 (en) * | 1994-06-24 | 1996-01-04 | Gruenenthal Gmbh | Use of lactam compounds as active pharmaceutical ingredients |
US5795368A (en) * | 1996-03-01 | 1998-08-18 | O.I. Corporation | Microtrap sample concentrator and methods of use |
DE19613976C1 (en) * | 1996-04-09 | 1997-11-20 | Gruenenthal Gmbh | Thalidomide prodrugs with immunomodulatory effects |
US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
DE69717831T3 (en) * | 1996-07-24 | 2018-08-30 | Celgene Corp. | SUBSTITUTED 2- (2,6-DIOXOPIPERIDIN-3-YL) -PHTHALIMIDES AND -1-OXOISOINDOLINES AND METHOD FOR REDUCING THE TNF-ALPHA MIRROR |
HU228769B1 (en) * | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US5798368A (en) * | 1996-08-22 | 1998-08-25 | Celgene Corporation | Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels |
DE69720735T9 (en) * | 1996-08-12 | 2005-08-25 | Celgene Corp. | IMMUNOTHERAPEUTIC AGENTS AND ITS APPLICATION IN REDUCING CYTOKININ VALUES |
ATE305301T1 (en) * | 1996-11-05 | 2005-10-15 | Childrens Medical Center | AGENTS FOR INHIBITING ANGIOGENESIS CONTAINING THALODOMIDE AND AN NSAID |
US5874448A (en) * | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
CN100390163C (en) * | 1998-03-16 | 2008-05-28 | 赛尔金有限公司 | 2-(2,6-dioxopiperidin-3-yl)-isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines |
US6673828B1 (en) * | 1998-05-11 | 2004-01-06 | Children's Medical Center Corporation | Analogs of 2-Phthalimidinoglutaric acid |
EP1165516B1 (en) * | 1999-03-12 | 2004-10-06 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic urea and related compounds useful as anti-inflammatory agents |
ES2250121T3 (en) * | 1999-03-18 | 2006-04-16 | Celgene Corporation | 1-OXO- AND 1,3-DIOXOISOINDOLINAS AND ITS EMPLOYMENT IN PHARMACEUTICAL COMPOSITIONS FOR THE REDUCTION OF LEVELS OF INFLAMMATORY CITOCINES. |
US7182953B2 (en) * | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
MXPA02009665A (en) * | 2000-03-31 | 2005-09-08 | Celgene Corp | Inhibition of cyclooxygenase 2 activity. |
US6458810B1 (en) * | 2000-11-14 | 2002-10-01 | George Muller | Pharmaceutically active isoindoline derivatives |
ATE374609T1 (en) | 2000-11-30 | 2007-10-15 | Childrens Medical Center | SYNTHESIS OF 4-AMINOTHALIDOMIDE ENANTIOMERS |
US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
US20030045552A1 (en) | 2000-12-27 | 2003-03-06 | Robarge Michael J. | Isoindole-imide compounds, compositions, and uses thereof |
WO2002068414A2 (en) * | 2001-02-27 | 2002-09-06 | The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
JP4494013B2 (en) | 2001-08-06 | 2010-06-30 | ザ チルドレンズ メディカル センター コーポレイション | Synthesis and antitumor activity of nitrogen-substituted thalidomide derivatives |
JP2005536189A (en) | 2002-04-12 | 2005-12-02 | セルジーン・コーポレーション | Method for identifying modulators of angiogenesis, compounds found thereby and therapeutic methods using the compounds |
US7498171B2 (en) * | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
CN1697655B (en) | 2002-05-17 | 2013-09-18 | 细胞基因公司 | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
AU2003286663B2 (en) | 2002-10-24 | 2009-08-13 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
NZ540186A (en) | 2002-10-31 | 2008-03-28 | Celgene Corp | Composition for the treatment of macular degeneration |
US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
UA83504C2 (en) * | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
NZ548049A (en) * | 2003-12-02 | 2009-01-31 | Celgene Corp | Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
NZ550026A (en) | 2004-03-22 | 2009-10-30 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders |
US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
BRPI0418742A (en) | 2004-04-14 | 2007-09-11 | Celgene Corp | methods of treating, preventing or controlling a myelodysplastic syndrome, reducing or preventing an adverse effect associated with the administration of a second active ingredient in a patient suffering from a myelodysplastic syndrome, pharmaceutical composition, single unit dosage form, and kit |
CA2563810A1 (en) | 2004-04-23 | 2005-11-10 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension |
WO2005112928A1 (en) | 2004-05-05 | 2005-12-01 | Celgene Corporation | Method of using and compositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases |
-
1997
- 1997-07-24 HU HU9903929A patent/HU228769B1/en active Protection Beyond IP Right Term
-
1998
- 1998-05-28 CN CNA2006101262647A patent/CN1911927A/en active Pending
- 1998-05-28 TR TR200000107T patent/TR200000107T2/en unknown
- 1998-05-28 PL PL337124A patent/PL193276B1/en unknown
- 1998-05-28 DE DE1998625994 patent/DE69825994T2/en not_active Expired - Lifetime
- 1998-05-28 ES ES08009864T patent/ES2403102T3/en not_active Expired - Lifetime
- 1998-05-28 CA CA 2291218 patent/CA2291218C/en not_active Expired - Fee Related
- 1998-05-28 ES ES04077432T patent/ES2309443T3/en not_active Expired - Lifetime
- 1998-05-28 DK DK98924959T patent/DK0984955T3/en active
- 1998-05-28 CN CN98805614A patent/CN1258293A/en active Pending
- 1998-05-28 PT PT04077432T patent/PT1486496E/en unknown
- 1998-05-28 SK SK1630-99A patent/SK163099A3/en unknown
- 1998-05-28 CN CNA2005100525903A patent/CN1680367A/en active Pending
- 1998-05-28 EP EP20040077432 patent/EP1486496B1/en not_active Expired - Lifetime
- 1998-05-28 NZ NZ501429A patent/NZ501429A/en not_active IP Right Cessation
- 1998-05-28 AT AT04077432T patent/ATE401319T1/en active
- 1998-05-28 EP EP20080009864 patent/EP1956017B1/en not_active Expired - Lifetime
- 1998-05-28 PT PT98924959T patent/PT984955E/en unknown
- 1998-05-28 TR TR200500299T patent/TR200500299T2/en unknown
- 1998-05-28 KR KR10-1999-7011076A patent/KR100526212B1/en not_active IP Right Cessation
- 1998-05-28 AU AU77012/98A patent/AU741982B2/en not_active Ceased
- 1998-05-28 DE DE69839739T patent/DE69839739D1/en not_active Expired - Lifetime
- 1998-05-28 RU RU99128073A patent/RU2209207C2/en not_active IP Right Cessation
- 1998-05-28 AT AT98924959T patent/ATE275139T1/en active
- 1998-05-28 EP EP19980924959 patent/EP0984955B1/en not_active Expired - Lifetime
- 1998-05-28 DK DK04077432T patent/DK1486496T3/en active
- 1998-05-28 TR TR201005282T patent/TR201005282T2/en unknown
- 1998-05-28 HU HU0003217A patent/HU229578B1/en not_active IP Right Cessation
- 1998-05-28 CA CA 2669481 patent/CA2669481C/en not_active Expired - Fee Related
- 1998-05-28 CZ CZ0427899A patent/CZ299812B6/en not_active IP Right Cessation
- 1998-05-28 TR TR200801878T patent/TR200801878T2/en unknown
- 1998-05-28 WO PCT/US1998/010886 patent/WO1998054170A1/en active Application Filing
- 1998-05-28 ES ES98924959T patent/ES2229497T3/en not_active Expired - Lifetime
- 1998-05-28 US US09/445,002 patent/US6395754B1/en not_active Expired - Lifetime
- 1998-05-28 JP JP50090999A patent/JP4307567B2/en not_active Expired - Fee Related
-
1999
- 1999-11-23 NO NO19995751A patent/NO322080B1/en not_active IP Right Cessation
- 1999-11-23 FI FI992490A patent/FI19992490A/en unknown
-
2002
- 2002-05-10 US US10/143,416 patent/US20020173658A1/en not_active Abandoned
-
2005
- 2005-01-14 US US11/035,817 patent/US7459466B2/en not_active Expired - Fee Related
- 2005-03-08 HK HK05102027A patent/HK1072248A1/en not_active IP Right Cessation
- 2005-08-11 MC MC225K patent/MC225A7/en unknown
-
2006
- 2006-03-30 NO NO20061455A patent/NO331367B1/en not_active IP Right Cessation
-
2008
- 2008-09-17 CY CY081101005T patent/CY1108348T1/en unknown
-
2009
- 2009-02-06 JP JP2009025981A patent/JP2009138009A/en active Pending
- 2009-08-18 NO NO20092860A patent/NO332270B1/en not_active IP Right Cessation
-
2011
- 2011-11-08 NO NO20111536A patent/NO332271B1/en not_active IP Right Cessation
-
2012
- 2012-03-06 NO NO2012004C patent/NO2012004I2/en unknown
- 2012-03-20 NO NO20120330A patent/NO333641B1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MC225A7 (en) | Substitutes 2- (2,6-Dioxopiperidin-3-yl) -phthalimides and-1-oxo-iso-indolines and methods for reducing tnf-alpha levels | |
HK1049004A1 (en) | Nitrogenous cyclic compounds and pharmaceutical compositions containing the same | |
ATE164575T1 (en) | SUBSTITUTED AROMATIC COMPOUNDS AS CAMP PHOSPHODIESTERASE AND TNF INHIBITORS | |
SE0000772D0 (en) | Chemical compounds | |
DE69332792T2 (en) | 4,1-Benzoxazepine derivatives as squalene synthetase inhibitors and their use for the treatment of hypercholesteremia and as fungicides | |
HK1072770A1 (en) | Bicyclic compound | |
EA200000614A1 (en) | 2,3-SUBSTITUTED INDO COMPOUNDS AS SOH-2 INHIBITORS | |
NO983493L (en) | New benzimidazole, benzoxazole and benzothiazole compounds, process for their preparation and pharmaceutical compositions containing such | |
NO972887L (en) | Piperidinedacetic acid derivatives useful as fibrinogen antagonist agent | |
AU633408B2 (en) | New imidazo (1,2-c) derivatives, process for the preparation thereof and pharmaceutical compositions containing them | |
DK0494816T3 (en) | Derived from 1,4-dihydropyridine, process for its preparation and therapeutic composition containing these | |
DK0412058T3 (en) | 1-Acyl-2-pyrrolidinones as learning and memory enhancers and pharmaceutical compositions containing these compounds | |
EA200101109A1 (en) | DERIVATIVES 1-TRIFTOROMETHYL-4-HYDROXY-7-PIPERIDINYL-AMINOMETHILKHROMAN | |
TW350835B (en) | Process for preparing nitroaniline derivatives | |
SE8800863D0 (en) | 3- (2-HALOETHYL) -1,4-OXATHIINS AND 2- (2-HALOETHYL) -1,4-DITHIINS AND TREATMENT OF LEUKEMIA AND TUMORS THEREWITH | |
EP1120415A4 (en) | Substituted isoxazolylthiophene compounds | |
MY133207A (en) | Substituted benzolactam compaunds | |
ATE66475T1 (en) | AROMATIC THIOAETHER. | |
ATE500241T1 (en) | PHENYL AND PYRIDYL PIPERIDINE WITH TNF ACTION | |
ES2107376A1 (en) | New pyrimidone derivatives having antifungal activity |